文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

预测 CAR-T 细胞治疗 B 细胞急性淋巴细胞白血病患者的严重 CRS 并确定生物标志物。

Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells.

机构信息

Intelligent Systems Science and Engineering College, Harbin Engineering University, Harbin, China.

Shanghai Unicar-Therapy BioMedicine Technology Co., Ltd, Shanghai, China.

出版信息

Front Immunol. 2023 Oct 3;14:1273507. doi: 10.3389/fimmu.2023.1273507. eCollection 2023.


DOI:10.3389/fimmu.2023.1273507
PMID:37854590
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10579557/
Abstract

INTRODUCTION: CAR-T cell therapy is a novel approach in the treatment of hematological tumors. However, it is associated with life-threatening side effects, such as the severe cytokine release syndrome (sCRS). Therefore, predicting the occurrence and development of sCRS is of great significance for clinical CAR-T therapy. The study of existing clinical data by artificial intelligence may bring useful information. METHODS: By analyzing the heat map of clinical factors and comparing them between severe and non-severe CRS, we can identify significant differences among these factors and understand their interrelationships. Ultimately, a decision tree approach was employed to predict the timing of severe CRS in both children and adults, considering variables such as the same day, the day before, and initial values. RESULTS: We measured cytokines and clinical biomarkers in 202 patients who received CAR-T therapy. Peak levels of 25 clinical factors, including IFN-γ, IL6, IL10, ferritin, and D-dimer, were highly associated with severe CRS after CAR T cell infusion. Using the decision tree model, we were able to accurately predict which patients would develop severe CRS consisting of three clinical factors, classified as same-day, day-ahead, and initial value prediction. Changes in serum biomarkers, including C-reactive protein and ferritin, were associated with CRS, but did not alone predict the development of severe CRS. CONCLUSION: Our research will provide significant information for the timely prevention and treatment of sCRS, during CAR-T immunotherapy for tumors, which is essential to reduce the mortality rate of patients.

摘要

简介:嵌合抗原受体 T 细胞(CAR-T)疗法是治疗血液系统肿瘤的一种新方法。然而,它与危及生命的副作用相关,如严重细胞因子释放综合征(sCRS)。因此,预测 sCRS 的发生和发展对于临床 CAR-T 治疗具有重要意义。通过人工智能对现有临床数据的研究可能会带来有用的信息。

方法:通过分析临床因素的热图,并比较严重和非严重 CRS 之间的差异,我们可以识别出这些因素之间的显著差异,并了解它们之间的相互关系。最终,采用决策树方法来预测儿童和成人严重 CRS 的发生时间,考虑了当天、前一天和初始值等变量。

结果:我们对接受 CAR-T 治疗的 202 名患者测量了细胞因子和临床生物标志物。在 CAR-T 细胞输注后,25 种临床因素的峰值水平,包括 IFN-γ、IL6、IL10、铁蛋白和 D-二聚体,与严重 CRS 高度相关。使用决策树模型,我们能够准确预测哪些患者会出现严重 CRS,包括三个临床因素,分别为当天、前一天和初始值预测。血清生物标志物(如 C 反应蛋白和铁蛋白)的变化与 CRS 相关,但不能单独预测严重 CRS 的发生。

结论:我们的研究将为肿瘤患者接受 CAR-T 免疫治疗期间 sCRS 的及时预防和治疗提供重要信息,这对于降低患者死亡率至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2f/10579557/9292e111016c/fimmu-14-1273507-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2f/10579557/c4742e5cb941/fimmu-14-1273507-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2f/10579557/2617f07edb52/fimmu-14-1273507-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2f/10579557/d2fb011ce2f7/fimmu-14-1273507-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2f/10579557/710acf825b33/fimmu-14-1273507-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2f/10579557/9292e111016c/fimmu-14-1273507-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2f/10579557/c4742e5cb941/fimmu-14-1273507-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2f/10579557/2617f07edb52/fimmu-14-1273507-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2f/10579557/d2fb011ce2f7/fimmu-14-1273507-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2f/10579557/710acf825b33/fimmu-14-1273507-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2f/10579557/9292e111016c/fimmu-14-1273507-g005.jpg

相似文献

[1]
Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells.

Front Immunol. 2023

[2]
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Cancer Discov. 2016-6

[3]
Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.

J Cell Mol Med. 2021-12

[4]
Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.

Adv Ther. 2019-8-19

[5]
Cytokine release syndrome after CAR T-cell therapy for B-cell acute lymphoblastic leukemia in children and young adolescents: storms make trees take deeper roots.

Expert Opin Pharmacother. 2024-8

[6]
Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy.

J Immunother. 2018

[7]
Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy.

Front Immunol. 2024

[8]
Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy.

Front Immunol. 2022

[9]
[Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].

Zhonghua Xue Ye Xue Za Zhi. 2023-10-14

[10]
Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy.

J Immunother Cancer. 2019-10-22

引用本文的文献

[1]
QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy.

NPJ Syst Biol Appl. 2025-6-11

[2]
Deep insight into cytokine storm: from pathogenesis to treatment.

Signal Transduct Target Ther. 2025-4-16

[3]
Clinical and Proteomic Insights into a Cytokine Release Syndrome Triggered by Tebentafusp in a Metastatic Uveal Melanoma Patient: Case Report.

J Clin Med. 2025-2-17

[4]
Hematologic cancers and infections: how to detect infections in advance and determine the type?

Front Cell Infect Microbiol. 2024

[5]
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies.

J Hematol Oncol. 2024-11-5

[6]
Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy.

Front Immunol. 2024

[7]
Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy.

J Transl Med. 2024-8-5

[8]
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.

Semin Immunopathol. 2024-7-16

[9]
CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.

Clin Rev Allergy Immunol. 2024-6

[10]
Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies.

J Transl Med. 2024-7-2

本文引用的文献

[1]
Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction.

Front Immunol. 2021

[2]
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.

Front Immunol. 2021

[3]
The Use of Visceral Proteins as Nutrition Markers: An ASPEN Position Paper.

Nutr Clin Pract. 2021-2

[4]
Coagulopathy in COVID-19.

J Thromb Haemost. 2020-9

[5]
Biomarkers in individualized management of chimeric antigen receptor T cell therapy.

Biomark Res. 2020-5-11

[6]
Role of procalcitonin use in the management of sepsis.

J Thorac Dis. 2020-2

[7]
Dissecting the Tumor-Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach.

Clin Cancer Res. 2020-7-15

[8]
Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies.

Biol Blood Marrow Transplant. 2020-5

[9]
CAR T Cell Toxicity: Current Management and Future Directions.

Hemasphere. 2019-3-29

[10]
Clinical lessons learned from the first leg of the CAR T cell journey.

Nat Med. 2019-9-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索